PD-1 agonist antibody - iBio Inc
Latest Information Update: 25 Sep 2023
At a glance
- Originator iBio Inc
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Programmed cell death 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 20 Jul 2023 Early research in Autoimmune disorders in USA (Parenteral), before July 2023 (iBio Inc pipeline, July 2023)